Company intelligence / Profile preview

PriveBio

USA

Ownership: Private
Development stage: Preclinical

Overview

PriveBio is developing first-in-class therapeutics targeting metabolic dysfunction and fibro-inflammation in cardiorenal metabolic diseases, using validated targets from human proteo-genomics data across large human datasets.

Therapeutic areas: GastroenterologyCardiovascularEndocrinologyNephrology
Modalities: Therapeutics
Industry: Biotech

Beyond the preview

Go deeper on PriveBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PriveBio.

Explore the full profile